Showing results (91-100 of 167) with videos related to
Sort By:
Pageof 17
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 10, 2021
Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung CancerJia Luo, Victoria L Martucci, Zoe Quandt, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2016
Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like SubsetsNatasha Rekhtman, Maria C Pietanza, Matthew D Hellmann, et al.Cancer Chemotherapy and Pharmacology|July 2, 2013
Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumabMatthew D Hellmann, Jamie E Chaft, Valerie Rusch, et al.The Oncologist|August 17, 2023
Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung CancerArielle Elkrief, Biagio Riccuiti, Joao V Alessi, et al.Journal for Immunotherapy of Cancer|July 24, 2023
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort studyArielle Elkrief, Joao M Victor Alessi, Biagio Ricciuti, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2022
Systemic and Oligo-Acquired Resistance to PD-(L)1 Blockade in Lung CancerAdam J Schoenfeld, Hira A Rizvi, Danish Memon, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 6, 2019
First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion TargetingNeeta Pandit-Taskar, Michael A Postow, Matthew D Hellmann, et al.The New England Journal of Medicine|October 23, 2023
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLCCaicun Zhou, Benjamin Solomon, Herbert H Loong, et al.The Journal of Experimental Medicine|December 22, 2021
TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasionMojdeh Shakiba, Paul Zumbo, Gabriel Espinosa-Carrasco, et al.The Journal of Experimental Medicine|May 23, 2022
Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functionsSara E Schad, Andrew Chow, Levi Mangarin, et al.Pageof 17